Pain Management in Prostate Cancer

Abstract Full-Text HTML Download Download as PDF (Size:270KB) PP. 164-172
DOI: 10.4236/oju.2012.223031    4,068 Downloads   6,881 Views   Citations

ABSTRACT

Prostate cancer is the most common urogenital malignity of western communities and is the second leading cause of cancer-related deaths in this population. Pain is often due to bone metastasis in prostate cancer. For the patient diagnosed with cancer and for his family, pain is the most feared aspect of cancer following the likelihood of failure to treat and death. Quality of life is severely impaired together with complaint of pain which arises high rates as 80% in advanced stage cancers.

Cite this paper

A. Eman, S. Gökhan Beyaz, H. Sağlam and M. Emre Gürcü, "Pain Management in Prostate Cancer," Open Journal of Urology, Vol. 2 No. 3A, 2012, pp. 164-172. doi: 10.4236/oju.2012.223031.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] F. J. Keefe, A. P. Abernethy and C. L. Campbell, “Psychological Approaches to Understanding and Treating Disease-Releated Pain,” Annual Review of Psychology, Vol. 56, 2005, pp. 1-22.
[2] D. M. Fitzgibbon and C. R. Chapman, “Cancer Pain: Asessment and Diagnosis,” In: J. D. Loeser, H. Butler, R. Chapman and D. C. Turk, Eds., Bonica’s Managment of Pain, 3rd Edition, Lippincott Williams and Wilkins, Philedelphia, 2001, pp. 623-658.
[3] R. Payne, “Choronic Pain: Challenges in the Assesment and Managment of Cancer Pain,” Journal of Pain and Symptom Management, Vol. 19, No. 1, 2000, pp. 12-15.
[4] S. L. Parker, T. Tong, S. Bolden and P. A. Wingo, “Cancer Statistics, 1997,” CA Cancer Journal Clinics, Vol. 47, No. 1, 1997, pp. 5-27.
[5] S. Ziaran, F. M. Goncalves and J. S. Breza, “Bone Mineral Density, Pathological Fractures and Bisphosphonate Therapy in Prostate Cancer Patients on Androgen Deprivation Therapy,” Endocrine Regulations, Vol. 45, No. 4, 2011, pp. 199-204.
[6] R. W. Ross and E. J. Smal, “Osteoporosis in Men Treated with Androgen Deprivation Therapy for Prostate Cancer,” Journal of Urology, Vol. 167, No. 5, 2002, pp. 1952-1956.
[7] R. E. Coleman, “Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity,” Clinical Cancer Research, Vol. 12, No. 20, 2006, pp. 6243-6249.
[8] R. E. Coleman, “Metastatic Bone Disease: Clinical Features, Pathophysiology and Treatment Strategies,” Cancer Treatment Reviews, Vol. 27, No. 3, 2001, pp. 165-176.
[9] A. Berruti, L. Dogliotti, R. Bitossi, G. Fasolis, G. Gorzegno, M. Bellina, et al., “Incidence of Skeletal Complications in Patients with Bone Metastatic Prostate Cancer and Hormone Refractory Disease: Predictive Role of Bone Resorption and Formation Markers Evaluated at Baseline,” Journal of Urology, Vol. 164, No. 4, 2000, pp. 1248-1253.
[10] C. Ripamonti and F. Fulfaro, “Malignant Bone Pain: Pathophysiology and Treatments,” Current Review of Pain, Vol. 4, No. 3, 2000, pp. 187-196.
[11] S. Buga and J. E. Sarria, “The Management of Pain in Metastatic Bone Disease,” Cancer Contrology, Vol. 19, No. 2, 2012, pp. 154-166.
[12] R. Payne, “Mechanisms and Management of Bone Pain,” Cancer, Vol. 80, No. 1, 1997, pp. 1608-1613.
[13] M. Uyar and Y. Yildirim, “Assesment of the Patient with Painful,” In: F. Tüzüner, Ed., Anesthesia, Intensive Care, Pain management, Nobel Publishing, Ankara, 2010, pp. 1523-1533.
[14] T. Aldemir, “Pain Measurement in Patients with Painful,” In: S. Erdine, Ed., Pain, 2nd Edition, Nobel Publishing, Istanbul, 2007, pp. 93-97.
[15] I. Asik, “Cancer Pain Treatment,” In: F. Tüzüner, Ed., Anesthesia, Intensive Care, Pain management, Nobel Publishing, Ankara, 2010, pp. 1613-1633.
[16] D. F. Zech, S. Grond, J. Lynch, D. Hertel and K. A. Leh- mann, “Validation World Healt Organization Guidelines for Cancer Pain Relief: A 10 Year Prospective Study,” Pain, Vol. 63, 1995, pp. 65-76.
[17] World Health Organization, “Cancer Pain Relief,” WHO, Geneva, 1986.
[18] G. W. Hanks, F. deConno and N. Cherny, “Morphine and Alternative Opioids in Cancer Pain: The EAPC Recommendations,” British Journal of Cancer, Vol. 84, 2001, pp. 587-593.
[19] N. I. Chernyand R. K. Portenoy, “Cancer Pain: Principles of Assessment and Syndromes,” In: R. Melzack and P. D. Wall, Eds., Textbook of Pain, 4th Edition, Churchill Livingstone, Edinburg, 1999, pp. 1017-1064.
[20] M. J. Lema, M. R. Day and D. P. Myers, “Cancer Pain,” In: P. R. Raj, Ed., Practical Management of Pain, 3rd Edition, Mosby, St. Louis, 2000, pp. 241-253.
[21] N. Cherny, “Cancer Pain Syndromes,” In: R. Melzack and P. D. Wall, Eds., Handbook of Pain Management, Churchill Livingstone, Edinburg, 2003, pp. 603-639.
[22] C. Hebbes and D. Lambert, “Non-Opioid Analgesics,” Anaesthesia & Intensive Care Medicine, Vol. 12, No. 2, 2011, pp. 69-72.
[23] J. P. Barbara, “Opioid Mechanisms and Opioid Drugs,” Anaesthesia & Intensive Care Medicine, Vol. 6, No. 1, 2005, pp. 25-29.
[24] N. Rawal, “Postoperative Pain Management,” In: S. Erdine, Ed., Pain, 2nd Edition, Nobel Publishing, Istanbul, 2007, pp. 118-135.
[25] D. M. Fitzgibbon, “Cancer Pain: Management,” In: J. D. Loeser, H. Butler, R. Chapman and D. C. Turk, Eds., Bonica’s Management of Pain, 3rd Edition, Lippincott Williams and Wilkins, Philadelphia, 2001, pp. 659-673.
[26] N. I. Cherny and R. K. Portenoy, “Practical Issues in the Management of Cancer Pain,” In: P. D. Wall and R. Melzack, Eds., Textbook of Pain, 4th Edition, Churchill Livingstone, Edinburg, 1999, pp. 1479-1523.
[27] R. Botting and S. S. Ayoub, “COX3 and the Mechanism of Action of Paracetamol/Acetaminophen,” Prostaglandins, Leukotriens and Essential Fatty Acids, Vol. 72, 2005, pp. 85-87.
[28] R. M. Botting, “Mechanism of Action of Acetaminophen: Is There a Cyclooxygenase 3?” Clinical Infectious Di- seases, Vol. 31, No. 5, 2000, pp. S202-S210.
[29] G. G. Graham, K. F. Scott and R. O. Day, “Tolerability of Paracetamol,” Drug Safety, Vol. 28, 2005, pp. 227-240.
[30] R. N. Brogden, “Pyrazolone Derivatives,” Drugs, Vol. 32, No. 14, 1986, pp. 60-70.
[31] K. Keskinbora, “Opioid Analgesics,” In: S. Erdine, Ed., Pain, 2nd Edition, Nobel Publishing, Istanbul, 2007, pp. 581-604.
[32] C. Sweeney and E. Bruera, “Opioids,” In: R. Melzack and P. D. Wall, Eds., Handbook of Pain Management, Churchill Livingstone, Edinburg, 2003, pp. 377-396.
[33] S. A. Schug and N. Gandham, “Opioids: Clinical Use,” In: S. B. McMahon and M. Koltzenberg, Eds., Wall and Melzack’s Textbook of Pain, 5th Edition, Elsevier Churchill Livingstone, Beijing, 2006, pp. 443-457.
[34] D. Lussier, A. G. Huskey and P. K. Portenoy, “Adjuvant Analgesic in Cancer Pain Management,” The Oncologist, Vol. 9, 2004, pp. 571-591.
[35] S. G. Beyaz, F. Bayar and A. F. Erdem, “Acute Postoperative Pain,” Journal of Anesthesia & Clinical Research, 2011, in press. doi:10.4172/2155-6148.S7-002
[36] A. Turan, B. Karamanlioglu, D. Memis, P. Usar, Z. Pamukcu and M. Ture, “The Analgesic Effects of Gaba- pentin after Total Abdominal Hysterectomy,” Anesthesia & Analgesia, Vol. 98, 2004, pp. 1370-1373.
[37] K. Y. Ho, T. J. Gan and A. S. Habib, “Gabapentin and Postoperative Pain: A Systematic Review of Randomized Controlled Trials,” Pain, Vol. 126, 2006, pp. 91-101.
[38] A. Turan, G. Kaya, B. Karamanlioglu, Z. Pamukcu and C. C. Apfel, “Effect of Oral Gabapentin on Postoperative Epidural Analgesia,” British Journal of Anaesthesia, Vol. 96, 2006, pp. 242-246.
[39] M. G. Rorarius, S. Mennander, S. Rintala, A. Puura, P. Suominen, R. Pirhonen, et al., “Gabapentin for the Prevention of Postoperative Pain after Vaginal Hysterectomy,” Pain, Vol. 110, 2004, pp. 175-181.
[40] S. Y. Kim, J. W. Song, B. Park, S. Park, Y. J. An and Y. H. Shim, “Pregabalin Reduces Post-Operative Pain after Mastectomy: A Double-Blind, Randomized, Placebo-Controlled Study,” Acta Anaesthesiologica Scandinavica, Vol. 55, No. 3, 2011, pp. 290-296.
[41] I. Gilron, D. Wajsbrot, F. Therrien and J. Lemay, “Pregabalin for Peripheral Neuropathic Pain: A Multicenter, Enriched Enrollment Randomized Withdrawal Placebo-Controlled Trial,” Clinical Journal of Pain, Vol. 27, No. 3, 2011, pp. 185-193.
[42] D. K. Baidya, A. Agarwal, P. Khanna and M. K. Arora, “Pregabalin in Acute and Chronic Pain,” Journal of Anaesthesiology Clinical Pharmacology, Vol. 27, No. 3, 2011, pp. 307-314.
[43] D. Ceyhan and M. S. Gülec, “Is Postoperative Pain Only a Nociceptive Pain?” Agri, Vol. 22, No. 2, 2010, pp. 47-52.
[44] R. H. Dworkin, A. B. O’Connor and J. Audette, “Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature Update,” Mayo Clinical Proceedings, Vol. 85, 2010, pp. 3-14.
[45] C. T. Hartrick and R. J. Rozek, “Tapentadol in Pain Management: A μ-Opioid Receptor Agonist and Noradrenaline Reuptake Inhibitor,” CNS Drugs, Vol. 25, No. 5, 2011, pp. 359-370.
[46] W. E. Wade and W. J. Spruill, “Tapentadol Hydrochloride: A Centrally Acting Oral Analgesic,” Clinical Therapy, Vol. 31, No. 12, 2009, pp. 2804-2818.
[47] M. Afilalo, J. U. Stegmann and D. Upmalis, “Tapentadol Immediate Release: A New Treatment Option for Acute Pain Management,” Journal of Pain Research, Vol. 3, 2010, pp. 1-9.
[48] N. Vadivelu, A. Timchenko, Y. Huang and R. Sinatra, “Tapentadol Extended-Release for Treatment of Chronic Pain: A Review,” Journal of Pain Research, Vol. 4, 2011, pp. 211-218.
[49] G. Vorsanger, J. Xiang, A. Okamoto, D. Upmalis and B. Moskovitz, “Evaluation of Study Discontinuations with Tapentadol Inmmediate Release and Oxycodone Immediate Release in Patients with Low Back or Osteoarthritis Pain,” Journal of Opioid Management, Vol. 6, No. 3, 2010, pp. 169-179.
[50] M. Etropolski, K. Kelly, A. Okamoto and C. Rauschkolb, “Comparable Efficacy and Superior Gastrointestinal Tolerability (Nausea, Vomiting, Constipation) of Tapentadol Compared with Oxycodone Hydrochloride,” Advances in Therapy, Vol. 28, No. 5, 2011, pp. 401-417.
[51] M. S. Cepeda, A. Sutton, R. Weinstein and M. Kim, “Effect of Tapentadol Extended Release on Productivity: Results From an Analysis Combining Evidence From Multiple Sources,” Journal of Pain, 2011, in press.
[52] S. Mercadante, F. Fulfaro and A. Casuccio, “The Use of Corticosteroids in Home Palliative Care,” Support Care Cancer, Vol. 9, No. 5, 2001, pp. 386-389.
[53] F. Saad, D. M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe, et al., “A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients with Hormone-Refractory Metastatic Prostate Carcinoma,” Journal of the National Cancer Institute, Vol. 94, No. 19, 2002, pp. 1458-1468.
[54] M. N. Gaze, C. G. Kelly, G. R. Kerr, A. Cull, V. J. Cowie, A. Gregor, et al., “Pain Relief and Quality of Life Following Radiotherapy for Bone Metastases: A Randomised Trial of Two Fractionation Schedules,” Radiotherapy & Oncology, Vol. 45, No. 2, 1997, pp. 109-116.
[55] J. S. Wu, A. Bezjak, E. Chow and P. Kirkbride, “Primary treatment Endpoint Following Palliative Radiotherapy for Painful Bone Metastases: Need for a Consensus Definition?” Clinical Oncology (Royal College of Radiologists), Vol. 14, No. 1, 2002, pp. 70-77.
[56] M. D. Brundage, J. M. Crook and H. Lukka, “Use of Strontium-89 in endocrine-Refractory Prostate Cancer Metastatic to Bone, Provincial Genitourinary Cancer Disease Site Group,” Cancer Prevention and Control, Vol. 2, No. 2, 1998, pp. 79-87.
[57] A. T. Porter, A. J. McEwan, J. E. Powe, R. Reid, D. G. McGowan, H. Lukka, et al., “Results of a Randomized Phase-III Trial to Evaluate the Efficacy of Strontium-89 Adjuvant to Local Field External Beam Irradiation in the Management of Endocrine Resistant Metastatic Prostate Cancer,” International Journal of Radiation Oncology & Biology & Physics, Vol. 25, No. 5, 1993, pp. 805-813.
[58] D. Niv and M. Gofeld, “Percutaneus Neural Destructive Techniques,” In: J. Michael, M. J. Cousins, T. T. Horlockert, D. B. Carr and P. O. Bridenburg, Eds., Cousins and Bridenbaugh’s Neural Blockade in Clinical Anesthesia and Pain Medicine, 4th Edition, Lippinocott Williams and Wilkins, Philadelphia, 2009, pp. 991-1036.
[59] S. E. Brogan, “Interventional Pain Therapies,” In: S. M. Fishman, J. C. Balantyne and J. P. Rathmell, Eds., Bonica’s Management of Pain, 4th Edition, Lippincott Williams and Wilkins, Philadelphia, 2010, pp. 605-618.
[60] M. Curatolo and N. Bogduk, “Diagnostic and Therapeutic Nerve Blocks,” In: S. M. Fishman, J. C. Balantyne and J. P. Rathmellb, Eds., Bonica’s Management of Pain, 4th Edition, Lippincott Williams and Wilkins, Philadelphia, 2010, pp. 1401-1423.
[61] P. C. Phan, “Treatment of Cancer Pain: Role of Neural Blockade and Neuromodulation,” In: J. Michael, M. J. Cousins, T. T. Horlockertt, D. B. Carr and P. O. Bridenburg, Eds., Cousins & Bridenbaugh’s Neural Blockade in Clinical Anesthesia and Pain Medicine, 4th Editon, Lippincott Williams and Wilkins, Philadelphia, 2009, pp. 1111-1153.
[62] J. P. Rathmell, C. A. Pino and S. Ahmed, “Spinal Pain and the Role of Neural Blockade,” In: J. Michael, M. J. Cousins, T. T. Horlockertt, D. B. Carr and P. O. Bridenburg, Eds., Cousins and Bridenbaugh’s Neural Blockade in Clinical Anesthesia and Pain Medicine, 4th Edition, Lippinocott Williams and Wilkins, Philadelphia, 2009, pp. 1063-1111.

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.